000274045 001__ 274045
000274045 005__ 20250119000256.0
000274045 0247_ $$2doi$$a10.1007/s00415-024-12851-x
000274045 0247_ $$2pmid$$apmid:39708160
000274045 0247_ $$2pmc$$apmc:PMC11663154
000274045 0247_ $$2ISSN$$a0367-004X
000274045 0247_ $$2ISSN$$a0012-1037
000274045 0247_ $$2ISSN$$a0340-5354
000274045 0247_ $$2ISSN$$a1432-1459
000274045 0247_ $$2altmetric$$aaltmetric:172325730
000274045 037__ $$aDZNE-2025-00026
000274045 041__ $$aEnglish
000274045 082__ $$a610
000274045 1001_ $$aBarba, Lorenzo$$b0
000274045 245__ $$aCSF synaptic biomarkers and cognitive impairment in multiple sclerosis.
000274045 260__ $$aHeidelberg$$bSpringer$$c2024
000274045 3367_ $$2DRIVER$$aarticle
000274045 3367_ $$2DataCite$$aOutput Types/Journal article
000274045 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1736339986_683
000274045 3367_ $$2BibTeX$$aARTICLE
000274045 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000274045 3367_ $$00$$2EndNote$$aJournal Article
000274045 520__ $$aPeople with multiple sclerosis (PwMS) experience various degrees of cognitive impairment (CI). Synaptic dysfunction may contribute to CI in PwMS but cerebrospinal fluid (CSF) synaptic biomarkers are unexplored in MS.To assess the role of CSF synaptosomal-associated protein 25 (SNAP-25), β-synuclein, neurogranin and neurofilament light chain protein (NfL) in patients with early relapsing MS with and without CI.We measured CSF SNAP-25, β-synuclein, and neurogranin in 48 untreated PwMS and 50 controls with other neurological diseases (ONDs) and tested their associations with neuropsychological and MRI data.CSF synaptic protein levels did not discriminate between MS subjects and patients with ONDs, with only SNAP-25 values being slightly increased in MS (p = 0.009). CSF synaptic markers were positively correlated with each other and with CSF NfL. Moreover, lower biomarker levels were found to be correlated with longer disease duration and lower brain volumes (especially of the thalamus). Moreover, we found significantly lower CSF SNAP-25 (p = 0.025), β-synuclein (p = 0.044), and neurogranin (p = 0.007) levels in PwMS with vs. without domain-specific cognitive impairment.Lower CSF synaptic biomarker levels were found in PwMS with longer disease duration and lower brain volumes and may identify PwMS at risk of CI.
000274045 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000274045 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000274045 650_7 $$2Other$$aBeta-synuclein
000274045 650_7 $$2Other$$aCSF
000274045 650_7 $$2Other$$aCognitive impairment
000274045 650_7 $$2Other$$aMS
000274045 650_7 $$2Other$$aNeurogranin
000274045 650_7 $$2Other$$aSNAP-25
000274045 650_7 $$2NLM Chemicals$$aSynaptosomal-Associated Protein 25
000274045 650_7 $$0132654-77-4$$2NLM Chemicals$$aNeurogranin
000274045 650_7 $$2NLM Chemicals$$aBiomarkers
000274045 650_7 $$2NLM Chemicals$$aNeurofilament Proteins
000274045 650_7 $$2NLM Chemicals$$aneurofilament protein L
000274045 650_7 $$2NLM Chemicals$$aSNAP25 protein, human
000274045 650_7 $$2NLM Chemicals$$aalpha-Synuclein
000274045 650_2 $$2MeSH$$aHumans
000274045 650_2 $$2MeSH$$aFemale
000274045 650_2 $$2MeSH$$aMale
000274045 650_2 $$2MeSH$$aSynaptosomal-Associated Protein 25: cerebrospinal fluid
000274045 650_2 $$2MeSH$$aCognitive Dysfunction: cerebrospinal fluid
000274045 650_2 $$2MeSH$$aCognitive Dysfunction: etiology
000274045 650_2 $$2MeSH$$aCognitive Dysfunction: diagnosis
000274045 650_2 $$2MeSH$$aCognitive Dysfunction: diagnostic imaging
000274045 650_2 $$2MeSH$$aNeurogranin: cerebrospinal fluid
000274045 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000274045 650_2 $$2MeSH$$aAdult
000274045 650_2 $$2MeSH$$aMiddle Aged
000274045 650_2 $$2MeSH$$aNeurofilament Proteins: cerebrospinal fluid
000274045 650_2 $$2MeSH$$aMultiple Sclerosis, Relapsing-Remitting: cerebrospinal fluid
000274045 650_2 $$2MeSH$$aMultiple Sclerosis, Relapsing-Remitting: complications
000274045 650_2 $$2MeSH$$aMultiple Sclerosis, Relapsing-Remitting: diagnostic imaging
000274045 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000274045 650_2 $$2MeSH$$aalpha-Synuclein: cerebrospinal fluid
000274045 650_2 $$2MeSH$$aMultiple Sclerosis: cerebrospinal fluid
000274045 650_2 $$2MeSH$$aMultiple Sclerosis: complications
000274045 650_2 $$2MeSH$$aMultiple Sclerosis: diagnostic imaging
000274045 650_2 $$2MeSH$$aBrain: diagnostic imaging
000274045 7001_ $$aGaetani, Lorenzo$$b1
000274045 7001_ $$aSperandei, Silvia$$b2
000274045 7001_ $$aDi Sabatino, Elena$$b3
000274045 7001_ $$aAbu-Rumeileh, Samir$$b4
000274045 7001_ $$0P:(DE-2719)9002026$$aHalbgebauer, Steffen$$b5$$udzne
000274045 7001_ $$0P:(DE-2719)9001560$$aOeckl, Patrick$$b6$$udzne
000274045 7001_ $$aSteinacker, Petra$$b7
000274045 7001_ $$aParnetti, Lucilla$$b8
000274045 7001_ $$aDi FIlippo, Massimiliano$$b9
000274045 7001_ $$00000-0003-4273-4267$$aOtto, Markus$$b10
000274045 773__ $$0PERI:(DE-600)1421299-7$$a10.1007/s00415-024-12851-x$$gVol. 272, no. 1, p. 85$$n1$$p85$$tJournal of neurology$$v272$$x0367-004X$$y2024
000274045 8564_ $$uhttps://pub.dzne.de/record/274045/files/DZNE-2025-00026.pdf$$yOpenAccess
000274045 8564_ $$uhttps://pub.dzne.de/record/274045/files/DZNE-2025-00026.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000274045 909CO $$ooai:pub.dzne.de:274045$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000274045 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002026$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000274045 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001560$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000274045 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000274045 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000274045 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000274045 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000274045 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000274045 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000274045 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROL : 2022$$d2023-10-21
000274045 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000274045 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000274045 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-10-21$$wger
000274045 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000274045 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000274045 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000274045 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NEUROL : 2022$$d2023-10-21
000274045 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000274045 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000274045 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000274045 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000274045 9201_ $$0I:(DE-2719)5000077$$kClinical Study Center (Ulm)$$lClinical Study Center (Ulm)$$x0
000274045 9201_ $$0I:(DE-2719)5000073$$kAG Öckl$$lTranslational Mass Spectrometry and Biomarker Research$$x1
000274045 980__ $$ajournal
000274045 980__ $$aVDB
000274045 980__ $$aUNRESTRICTED
000274045 980__ $$aI:(DE-2719)5000077
000274045 980__ $$aI:(DE-2719)5000073
000274045 9801_ $$aFullTexts